Icon

VOTRIENT (nda022465)- (EQ 200MG BASE,EQ 400MG BASE)

PAZOPANIB HYDROCHLORIDE NOVARTIS
EQ 200MG BASE,EQ 400MG BASE
No No
2023-Oct-19 2014-Oct-19
2019-Apr-26 None
None No
VOTRIENT is a kinase inhibitor indicated for the treatment of patients with: • advanced renal cell carcinoma. • advanced soft tissue sarcoma who have received prior chemotherapy.
5 0 5
Total Other Developers 18
Drugs with Suitability No
EQ 200MG BASE ** ** - - -
EQ 400MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 3
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** *** ***** *** ************** ********** ******* *********** ****** **. ****, *****, ***** ********* ** ***** *** ***** ****** *** ***** *** *** ******, ***** (***) ***
****** **** ****** *** ***** ******** *.*.*. *********** ****** ****** ********** **, ******, *****, ******* (***) ***
****** ****** ****** ***. *********** *** ****** *****, *******, ******* *** ***, ****** (***) ***
****** ******* ***** **** ******* ******* *********** **** **. *-*/*, ****** ********** ****** ****** ********, *********** ********, ***** **** ******, ***** (***) ***
****** ******* ******* ******** ***. ***. *********** ** ** ***** ******* ********* *, ***** ********* ****** **** *, ********@******, ****** ******, ****** ******** *****, ******** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-*, **. **. ***, *** & ***, ******* *******, ********* ******, *******-**********, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.